Page last updated: 2024-08-23

cabergoline and Adenoma

cabergoline has been researched along with Adenoma in 107 studies

Research

Studies (107)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (1.87)	18.7374
1990's	11 (10.28)	18.2507
2000's	37 (34.58)	29.6817
2010's	39 (36.45)	24.3611
2020's	18 (16.82)	2.80

Authors

Authors	Studies
Auriemma, RS; Colao, A; Negri, M; Patalano, R; Pirchio, R; Pivonello, C; Pivonello, R	1
Campana, C; Canevari, FR; Caputo, M; Castelletti, L; Ferone, D; Ferrero, A; Gaggero, G; Gatto, F; Lania, A; Lavezzi, E; Marzullo, P; Nista, F; Rossi, DC; Zona, G	1
Cohen, D; Eshkoli, T; Fraenkel, M; Goldbart, A; Gorshtein, A; Greenman, Y; Shimon, I; Tsvetov, G; Yoel, U; Zaid, D	1
Boguszewski, CL; Botelho, MS; Franzini, ÍA; Nunes-Nogueira, VDS	1
Akirov, A; Ayalon-Dangur, I; Duskin-Bitan, H; Gorshtein, A; Robenshtok, E; Shimon, I; Tsvetov, G	1
Miller, KK; Tritos, NA	1
Farrant, MT; Gunn, AJ; Milsom, SR; O'Sullivan, SM; Ogilvie, CM	1
Okayama, A; Sato, T; Shimatsu, A; Yamaguchi, H	1
Arvigo, M; Bruzzone, E; Dogan, F; Feelders, RA; Ferone, D; Gatto, F; Hofland, L; Lamberts, S; van der Pas, R; van Koetsveld, P	1
Dekkers, OM; Fleseriu, M; Karavitaki, N	1
Kawakami, K; Matsubayashi, K	1
Biller, BMK; Tritos, NA	1
Giraldi, EA; Ioachimescu, AG	1
Abreu, C; Cadena-Obando, D; Cuevas-Ramos, D; Espinosa-de-Los-Monteros, AL; González-Virla, B; Ibarra-Salce, R; Mercado, M; Mercado-Cherem, A; Pérez-Reyes, SP; Portocarrero-Ortiz, LA; Sosa-Eroza, E; Talavera, JO; Vergara-López, A	1
Barlier, A; Brue, T; Culler, MD; Cuny, T; Datta, R; Defilles, C; Dufour, H; Figarella-Branger, D; Graillon, T; Halem, HA; Landsman, T; Mougel, G; Saveanu, A; Zhang, S	1
Duskin-Bitan, H; Gorshtein, A; Manisterski, Y; Masri, H; Rudman, Y; Shimon, I	1
Cai, L; Li, Q; Lu, J; Su, Z; Wang, C; Wu, Z; Xu, J; Xu, Y	1
Bronstein, MD; Greenman, Y	1
Agostini, H; Arnoux, A; Brailly-Tabard, S; Chanson, P; Kuhn, E; Massart, C; Mavromati, M; Piketty, ML; Souberbielle, JC; Young, J	1
Barkan, AL; Hollon, TC; Savastano, LE; Sullivan, SE	1
Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS	1
Seow, CJ; Young, WF	1
Croxson, MS; Holdaway, I; Kunasegaran, S; Murphy, R	1
Cosio, C; Fracassi, F; Garatti, M; Grinwis, GCM; Kooistra, HS; Luccardini, L; Sartori, E	1
Cha, HJ; Kim, JH; Kim, SW; Kim, YH; Lee, JH; Lee, SY; Paek, SH; Shin, CS	1
Akirov, A; Eizenberg, Y; Glaser, B; Greenman, Y; Mansiterski, Y; S'chigol, I; Shimon, I; Shraga-Slutzky, I	1
Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R	1
Reincke, M; Theodoropoulou, M	1
Batista, RL; Cescato, VAS; Cunha-Neto, MB; da Silva, GO; Herkenhoff, CGB; Medeiros, RSS; Musolino, NRC; Trarbach, EB	1
Arosio, M; Ferrante, E; Giavoli, C; Indirli, R; Mantovani, G; Sala, E	1
Bolanowski, M; Colao, A; Kerlan, V; Komorowski, J; Kos-Kudła, B; Minuto, FM; Scaroni, C; Tabarin, A; Zgliczyński, W	1
Asha, HS; Cherian, KE; Paul, TV; Rajan, R	1
Abucham, J; Boguszewski, CL; Bronstein, MD; Correa-Silva, SR; Czepielewski, MA; Duarte, FG; Gadelha, MR; Huayllas, MKP; Jallad, RS; Kasuki, L; Musolino, NR; Naves, LA; Ribeiro-Oliveira Junior, A; Soares, BS; Vilar, L	1
Abreu, A; Albarrán, AA; Carrasco, CA; Espinosa de los Monteros, AL; Gadelha, M; Mercado, M	1
Aller, J; Alvarez-Escolá, C; Bernabeu, I; Biagetti, B; Blanco, C; Cámara, R; Castells, I; Fajardo, C; García, R; Gaztambide, S; Mora, M; Picó, A; Pozo, CD; Resmini, E; Salinas, I; Sesmilo, G; Soto, A; Torres, E; Villabona, C; Webb, SM	1
Marek, J	1
Cleemann, L; Holm, K; Jarløv, AE; Lewis, A	1
Colli, LM; de Castro, M; Gadelha, MR; Gasparetto, EL; Kasuki, L; Marques, NV; Moraes, AB; Takiya, CM; Vieira Neto, L; Wildemberg, LE	1
Bronstein, MD; Fleseriu, M; Greenman, Y; Jallad, RS; Shimon, I; Yedinak, CG	1
Alfieri, A; Ballarino, MC; Boero, L; Chervin, A; Danilowicz, K; Diez, S; Fainstein Day, P; García-Basavilbaso, N; Glerean, M; Guitelman, M; Katz, D; Loto, MG; Mallea-Gil, MS; Manavela, M; Martinez, M; Miragaya, K; Moncet, D; Rogozinski, AS; Servidio, M; Stalldecker, G; Vitale, M	1
De Pue, A; Lutin, B; Paemeleire, K	1
Cooper, O; Gertych, A; Greenman, Y; Jonas-Kimchi, T; Melmed, S; Ram, Z; Robenshtok, E; Sagiv, N; Shimon, I; Stern, N; Yaish, I; Yuan, X	1
Dhanjal, MK; Knight, M; Lambert, K; McCance, DR; Rees, K; Seed, PT; Williamson, C	1
Barbieri, F; Culler, MD; Dong, J; Dufour, H; Feelders, RA; Florio, T; Gunz, G; Hofland, LJ; Jaquet, P; Moreau, JP; Saveanu, A; Spaziante, R; Stalla, GK; Taylor, JE; Theodoropoulou, M; van Koetsveld, PM; Zona, G	1
Bolu, E; Kebapcilar, L; Kutlu, M; Sahin, M; Taslipinar, A; Uckaya, G	1
Drake, WM; Metcalfe, KA; Moyes, VJ	1
Albuquerque, LA; Almeida, JP; Ferraz, CL; Ferraz, TM; Gondim, J; Mota, I	1
Matsuno, A	1
Ambrosio, MR; Buratto, M; Degli Uberti, EC; Filieri, C; Lapparelli, M; Minoia, M; Scanarini, M; Tagliati, F; Zatelli, MC	1
Coiré, CI; Horvath, E; Kovacs, K; Rosso, D; Smyth, HS	1
Benbassat, C; Grozinsky-Glasberg, S; Shimon, I; Tzvetov, G	1
Burger, P; Menucci, M; Quiñones-Hinojosa, A; Salvatori, R	1
Albuquerque, JL; Azevedo, MF; Casulari, LA; Faria, MS; Figueiredo, P; Montenegro, RM; Nascimento, GC; Naves, LA; Vilar, L	1
Bianchi, A; Carrozza, C; D'Ercole, M; Della Pepa, GM; Doglietto, F	1
Barbieri, F; Culler, MD; Ferone, D; Florio, T; Gatti, M; Gatto, F; Giusti, M; Hofland, LJ; Minuto, F; Ravetti, JL; Saveanu, A; Schulz, S; Wurth, R; Zona, G	1
DeCubellis, J; Donnelly, T; Kiupel, M; Mayer, J; Sato, A	1
Cottier, JP; François, P; Gilbert-Dussardier, B; Girard, JJ; Jan, M; Lecomte, P; Richard, S; Trouillas, J; Tudorancea, A	1
Ahmed, A; Furqan, S; Islam, N	1
Barahona Constanzo, MJ; del Pozo Picó, C	1
Fukuoka, H; Iguchi, G; Inoshita, N; Nishizawa, H; Suda, K; Takahashi, M; Takahashi, Y; Yamada, S; Yamamoto, M	1
Anand, KS; Dhikav, V	1
Bianchi, A; De Marinis, L; Doglietto, F; Giampietro, A; Iacovazzo, D; Lauriola, L; Lucci-Cordisco, E; Lugli, F; Milardi, D	1
Biesold, M; Guenzel, S; Lohmann, T; Paschke, R; Prothmann, S; Schober, R; Trantakis, C	1
Akintoye, SO; Bianco, P; Booher, S; Chebli, C; Cherman, N; Collins, MT; Feuillan, P; Kushner, H; Leroith, D; Robey, PG; Wientroub, S	1
Annunziato, L; Arvigo, M; Colao, A; De Caro, ML; de Herder, WW; Ferone, D; Hofland, LJ; Kros, JM; Lamberts, SW; Lombardi, G; Pivonello, R	1
Díez, JJ; Iglesias, P; Macho, LP	1
Casulari, LA; Mello, PA; Naves, LA; Papadia, C; Pereira Neto, A	1
Date, I; Hashimoto, K; Inagaki, K; Makino, H; Miyoshi, T; Ogura, T; Otsuka, F; Suzuki, J; Takeda, M	1
Gomes, MC; Knoepfelmacher, M; Melo, ME; Mendonca, BB	1
Rickels, MR; Snyder, PJ	1
Goadsby, PJ; Levy, MJ; Matharu, MS; Meeran, K; Powell, M	1
Góth, MI; Iván, G; Nagy, GM; Oláh, M; Szigeti-Csúcs, N	1
Boianov, M; Khristov, V; Vezenkova, L	1
Colao, A; De Leo, M; Di Sarno, A; Guerra, E; Lombardi, G; Mentone, A	1
Danilovic, DL; Knoepfelmacher, M; Mendonça, BB; Rosa Nasser, RH	1
Culler, MD; Dufour, H; Guillen, S; Gunz, G; Jaquet, P; Saveanu, A	1
de Herder, WW; Feelders, RA; Krenning, EP; Kwekkeboom, DJ; Reijs, AE; Tanghe, HL; van Aken, MO; van der Lely, AJ	1
Georgieva, J; Nussbaum, G; Rochlitz, H; Steinhoff, M; Zouboulis, CC	1
Enseñat, J; Mesa, J; Obiols, G; Ortega, A; Sahuquillo, J; Topcewski, T; Vilalta, J	1
Cappabianca, P; Colao, A; Cozzi, R; Ghigo, E; Martino, E; Scanarini, M	1
Tokhunts, KA	1
Greenman, Y	1
Ali, O; Banerjee, S; Kelly, DF; Lee, PD	1
Adamo, V; Manno, M; Marchesan, E; Tomei, F	1
Barlier, A; Brue, T; Jaquet, P; Saveanu, A	1
Ambrosi, B; Angioni, AR; Baglioni, S; Barbieri, AM; Beck-Peccoz, P; Borretta, G; Brogioni, S; Cannavò, S; Colao, A; Filopanti, M; Fustini, MF; Gasco, V; Gasperi, M; Grottoli, S; Jaffrain-Rea, ML; Lania, A; Mantovani, G; Monte, PD; Peri, A; Pigliaru, F; Spada, A	1
Ajossa, S; Depau, GF; Guerriero, S; Mais, V; Melis, GB; Paoletti, AM	1
Biller, BM; Cannistraro, KB; Davis, KR; Klibanski, A; Molitch, ME; Schoenfelder, JR; Simons, JA; Vance, ML	1
Jeffreys, R; Leese, G; Vora, J	1
Arosio, M; Biella, O; Faglia, G; Gambino, G; Muratori, M; Romano, C	1
Bertagna, A; Camanni, F; Camanni, M; Cammarota, T; Ciccarelli, E; Cirillo, S; Gaia, D; Grottoli, S; Razzore, P	1
Abs, R; Beckers, A; Coolens, JL; Mahler, C; Maiter, D; Nobels, F; Van Acker, K; Verhelst, J	1
Attanasio, R; Barausse, M; Branca, V; Cozzi, R; Da Re, N; Dallabonzana, D; Gelli, D; Oppizzi, G; Orlandi, P	1
Bartolone, L; Blandino, A; Cannavò, S; Galatioto, S; Spinella, S; Trimarchi, F	1
Abs, R; Beckers, A; Coremans, P; Lamberigts, G; Mahler, C; Maiter, D; Mockel, J; Petrossians, P; Raftopoulos, C; Stevenaert, A; van den Bruel, A; Vandeweghe, M; Velkeniers, B; Verhelst, J; Verlooy, J	1
Colao, A; Di Salle, F; Faggiano, A; Filippella, M; Lombardi, G; Pivonello, R	1
Cerbone, G; Colao, A; Di Sarno, A; Di Somma, C; Ferone, D; Lastoria, S; Lombardi, G; Lucci, R	1
Andersen, M; Bjerre, P; Edal, A; Hagen, C; Høilund-Carlsen, PF; Pedersen, PH; Schrøder, HD	1
Beckers, A; Bloch, B; Kalife, A; Petrossians, P; Ronci, N; Stevenaert, A; Tabarin, A; Valdés Socin, H	1
Maschek, W; Pichler, R	1
Agostini, S; Billeci, D; Conte, N; De Menis, E; Marton, E; Tramontin, P; Visentin, A	1
Cappabianca, P; Colao, A; Di Salle, F; Di Sarno, A; Di Somma, C; Faggiano, A; Landi, ML; Lombardi, G; Pivonello, R; Rossi, FW	1
Nippoldt, TB; Sheehan, MT	1
Góth, M; Hubina, E; Kovács, L; Szabolcs, I	1
Dominoni, P; Ferrari, L; Gianola, D; Gualteroni, L; Montini, M; Pagani, G; Pagani, MD; Sileo, F; Stroppa, S; Tengattini, F	1
Camanni, F; Ciccarelli, E; Giordano, G; Giusti, M; Miola, C; Potenzoni, F; Sghedoni, D	1
Cancio, E; Cocchi, D; Dall'Ara, A; Devesa, J; Di Salle, E; Lima, L; Müller, EE	1

Reviews

15 review(s) available for cabergoline and Adenoma

Article	Year
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. Frontiers in endocrinology, 2021, Volume: 12 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aminoquinolines; beta-Arrestins; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Filamins; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lisuride; MicroRNAs; Pergolide; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2	2021
Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature. Journal of endocrinological investigation, 2022, Volume: 45, Issue:8 Topics: Adenoma; Aged; Cabergoline; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pituitary Neoplasms; Prolactin; Retrospective Studies	2022
Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis. Pituitary, 2022, Volume: 25, Issue:6 Topics: Adenoma; Cabergoline; Humans; Pituitary Neoplasms	2022
Diagnosis and Management of Pituitary Adenomas: A Review. JAMA, 2023, 04-25, Volume: 329, Issue:16 Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Child; Female; Human Growth Hormone; Humans; Hypopituitarism; Pituitary Neoplasms; Pregnancy; Prolactinoma	2023
Advances in the Medical Treatment of Cushing Disease. Endocrinology and metabolism clinics of North America, 2020, Volume: 49, Issue:3 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Cabergoline; Endocrinology; Humans; Mifepristone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin; Treatment Outcome	2020
The Role of Dopamine Agonists in Pituitary Adenomas. Endocrinology and metabolism clinics of North America, 2020, Volume: 49, Issue:3 Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Human Growth Hormone; Humans; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2020
Advances in the medical treatment of Cushing's syndrome. The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:4 Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin	2019
Tumor-Directed Therapeutic Targets in Cushing Disease. The Journal of clinical endocrinology and metabolism, 2019, 03-01, Volume: 104, Issue:3 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Clinical Trials as Topic; Corticotrophs; Humans; Pituitary ACTH Hypersecretion; Roscovitine; Silybin; Somatostatin; Treatment Outcome; Tretinoin	2019
[Recent trends in the pathophysiology and treatment of pituitary adenomas]. Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:8 Topics: Adenoma; Antineoplastic Agents; Cabergoline; Corticotropin-Releasing Hormone; Dacarbazine; Ergolines; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypothalamic Hormones; Incidental Findings; Neurosurgical Procedures; Octreotide; Pituitary Neoplasms; Prolactinoma; Receptors, Neuropeptide; Receptors, Pituitary Hormone-Regulating Hormone; Temozolomide	2009
New prospects for drug treatment in Cushing disease. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012, Volume: 59, Issue:10 Topics: Adenoma; Adrenocorticotropic Hormone; Animals; Cabergoline; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Ergolines; Etomidate; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Metyrapone; Mice; Mifepristone; Mitotane; Multicenter Studies as Topic; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Pyridines; Rats; Somatostatin; Therapies, Investigational; Tretinoin	2012
Double pituitary adenomas. Endocrine, 2013, Volume: 43, Issue:2 Topics: Adenoma; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Comorbidity; Ergolines; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Treatment Outcome	2013
Treatment of pituitary tumors: dopamine agonists. Endocrine, 2005, Volume: 28, Issue:1 Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Receptors, Dopamine	2005
Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nature clinical practice. Endocrinology & metabolism, 2006, Volume: 2, Issue:4 Topics: Adenoma; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Prolactin; Prolactinoma; Sex Characteristics	2006
Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Molecular and cellular endocrinology, 2008, May-14, Volume: 286, Issue:1-2 Topics: Adenoma; Antineoplastic Agents, Hormonal; Cabergoline; Cell Proliferation; Dopamine; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Octreotide; Pituitary Neoplasms; Protein Multimerization; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin; Tumor Cells, Cultured	2008
[Novel pharmacologic therapies in acromegaly]. Orvosi hetilap, 2002, May-12, Volume: 143, Issue:19 Suppl Topics: Acromegaly; Adenoma; Aminoquinolines; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Hormones; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Prolactin; Receptors, Somatotropin; Somatostatin	2002

Trials

11 trial(s) available for cabergoline and Adenoma

Article	Year
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial. American journal of clinical oncology, 2019, Volume: 42, Issue:2 Topics: Adenoma; Antiparkinson Agents; Cabergoline; Disease Management; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm, Residual; Pituitary Neoplasms; Prognosis; Receptors, Dopamine D2; Survival Rate	2019
Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study Endokrynologia Polska, 2019, Volume: 70, Issue:4 Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Drug Therapy, Combination; Female; Human Growth Hormone; Humans; Longitudinal Studies; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Treatment Outcome	2019
Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary, 2001, Volume: 4, Issue:3 Topics: Adenoma; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Treatment Outcome; Visual Acuity	2001
[Suppression of hyperprolactinemia in pituitary microadenoma with cabergoline (Dostinex)]. Akusherstvo i ginekologiia, 2005, Volume: 44, Issue:5 Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactin; Treatment Outcome; Tumor Burden	2005
Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology, 2006, Volume: 83, Issue:3-4 Topics: Adenoma; Adult; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine; Drug Screening Assays, Antitumor; Ergolines; Female; Human Growth Hormone; Humans; Ligands; Male; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; Recombinant Fusion Proteins; RNA, Messenger; Somatostatin; Tumor Cells, Cultured	2006
[Comparative evaluation of effectiveness of treatment of hyperprolactinemia]. Georgian medical news, 2007, Issue:142 Topics: Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Ovulation; Pituitary Neoplasms; Treatment Outcome	2007
Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of endocrinological investigation, 1997, Volume: 20, Issue:9 Topics: Acromegaly; Adenoma; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin-Like Growth Factor I; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactin	1997
Cabergoline in the treatment of acromegaly: a study in 64 patients. The Journal of clinical endocrinology and metabolism, 1998, Volume: 83, Issue:2 Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prospective Studies	1998
Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? European journal of endocrinology, 1998, Volume: 139, Issue:5 Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin	1998
Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clinical endocrinology, 2000, Volume: 52, Issue:4 Topics: Adenoma; Adult; Aminoquinolines; Benzamides; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Patient Selection; Pituitary Neoplasms; Predictive Value of Tests; Prolactin; Prolactinoma; Radionuclide Imaging	2000
Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:11 Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Radioimmunoassay; Retrospective Studies	2001

Other Studies

81 other study(ies) available for cabergoline and Adenoma

Article	Year
Resistant prolactinomas: a case series of 26 patients. Endocrine, 2022, Volume: 77, Issue:2 Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Young Adult	2022
Natural history of nonfunctioning pituitary macroadenomas followed without intervention: A retrospective cohort study. Clinical endocrinology, 2023, Volume: 98, Issue:4 Topics: Adenoma; Aged; Aged, 80 and over; Cabergoline; Humans; Hypopituitarism; Male; Middle Aged; Pituitary Neoplasms; Retrospective Studies; Treatment Outcome	2023
An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists. The Australian & New Zealand journal of obstetrics & gynaecology, 2020, Volume: 60, Issue:3 Topics: Abortion, Spontaneous; Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Female; Humans; Infertility; Lactation; Pituitary Neoplasms; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Retrospective Studies; Young Adult	2020
Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. Endocrine journal, 2020, Feb-28, Volume: 67, Issue:2 Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Chemical and Drug Induced Liver Injury; Child; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemia; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Product Surveillance, Postmarketing; Radiotherapy; Receptors, Somatotropin; Somatostatin; Tumor Burden; Young Adult	2020
β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids. The Journal of endocrinology, 2020, Volume: 245, Issue:1 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Animals; Anti-Inflammatory Agents; beta-Arrestin 1; beta-Arrestin 2; Cabergoline; Cell Line, Tumor; Dexamethasone; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Ketoconazole; Male; Mice; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Gland; Pituitary Neoplasms	2020
Endocrinology in the time of COVID-19: Management of pituitary tumours. European journal of endocrinology, 2020, Volume: 183, Issue:1 Topics: Adenoma; Antineoplastic Agents, Hormonal; Cabergoline; Coronavirus Infections; COVID-19; Disease Management; Dopamine Agonists; Hormone Replacement Therapy; Human Growth Hormone; Humans; Neurosurgical Procedures; Octreotide; Pandemics; Peptides, Cyclic; Pituitary Apoplexy; Pituitary Neoplasms; Pneumonia, Viral; Practice Guidelines as Topic; Radiotherapy; Somatostatin; Telemedicine; Time Factors; Visual Field Tests	2020
Prevalence, incidence, comorbidities, and treatment patterns among Japanese patients with acromegaly: a descriptive study using a nationwide claims database. Endocrine journal, 2020, Oct-28, Volume: 67, Issue:10 Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Comorbidity; Dopamine Agonists; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hyperlipidemias; Hypertension; Incidence; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Prevalence; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Somatostatin; Young Adult	2020
Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry. The Journal of clinical endocrinology and metabolism, 2020, 12-01, Volume: 105, Issue:12 Topics: Acromegaly; Adenoma; Adult; Cabergoline; Combined Modality Therapy; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Mexico; Middle Aged; Neurosurgical Procedures; Postoperative Period; Prognosis; Registries; Retrospective Studies; Somatostatin; Treatment Outcome	2020
Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Pituitary, 2021, Volume: 24, Issue:3 Topics: Adenoma; Cabergoline; Dopamine; Human Growth Hormone; Humans; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin; Tumor Cells, Cultured	2021
True hyperprolactinemia in men without visible pituitary adenoma. Endocrine, 2021, Volume: 72, Issue:3 Topics: Adenoma; Adult; Aged; Cabergoline; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Young Adult	2021
Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas. Oxidative medicine and cellular longevity, 2021, Volume: 2021 Topics: Adenoma; Animals; Cabergoline; Dopamine Agonists; Female; Humans; Mice; Mice, Nude; Pituitary Neoplasms; Quassins; Xenograft Model Antitumor Assays	2021
Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma. European journal of endocrinology, 2021, Aug-27, Volume: 185, Issue:4 Topics: Adenoma; Cabergoline; Chemotherapy, Adjuvant; Disease Progression; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Neurosurgical Procedures; Patient Selection; Pituitary Neoplasms; Practice Patterns, Physicians'; Tumor Burden	2021
Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. The Journal of clinical endocrinology and metabolism, 2017, 08-01, Volume: 102, Issue:8 Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Drug Therapy, Combination; Dwarfism, Pituitary; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Immunoassay; Insulin-Like Growth Factor I; Male; Middle Aged; Neurosurgical Procedures; Somatostatin; Young Adult	2017
Korsakoff syndrome from retrochiasmatic suprasellar lesions: rapid reversal after relief of cerebral compression in 4 cases. Journal of neurosurgery, 2018, Volume: 128, Issue:6 Topics: Adenoma; Adult; Amnesia; Cabergoline; Cerebellar Diseases; Craniopharyngioma; Dopamine Antagonists; Humans; Korsakoff Syndrome; Male; Mammillary Bodies; Mental Disorders; Middle Aged; Nerve Compression Syndromes; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2018
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:8 Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult	2017
An Overlooked Cause of Hypokalemia. The American journal of medicine, 2017, Volume: 130, Issue:10 Topics: 14-alpha Demethylase Inhibitors; Adenoma; Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Female; Humans; Hypokalemia; Ketoconazole; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms	2017
An unusual case of Cushing's syndrome due to bihormonal ACTH-prolactin secreting pituitary macroadenoma with rapid response to cabergoline. BMJ case reports, 2017, Aug-07, Volume: 2017 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Young Adult	2017
Prolactinoma in a Dog. Veterinary pathology, 2017, Volume: 54, Issue:6 Topics: Adenoma; Animals; Cabergoline; Dogs; Dopamine Agonists; Ergolines; Fatal Outcome; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Tomography Scanners, X-Ray Computed	2017
The efficacy of medical treatment in patients with acromegaly in clinical practice. Endocrine journal, 2018, Jan-30, Volume: 65, Issue:1 Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Follow-Up Studies; Growth Hormone-Secreting Pituitary Adenoma; Hospitals, University; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Neoplasm Grading; Republic of Korea; Retrospective Studies; Somatostatin; Tumor Burden	2018
IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas. Pituitary, 2018, Volume: 21, Issue:4 Topics: Acromegaly; Adenoma; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactinoma	2018
Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas. Hormones & cancer, 2019, Volume: 10, Issue:2-3 Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Postmenopause; Premenopause; Prolactin; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Risk; Treatment Outcome; Young Adult	2019
McCune Albright syndrome: an endocrine medley. BMJ case reports, 2019, Jul-15, Volume: 12, Issue:7 Topics: Adenoma; Bone Density Conservation Agents; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Female; Fibrous Dysplasia, Polyostotic; Humans; Hyperthyroidism; Leg; Musculoskeletal Pain; Pituitary Neoplasms; Rare Diseases; Young Adult; Zoledronic Acid	2019
Brazilian multicenter study on pegvisomant treatment in acromegaly. Archives of endocrinology and metabolism, 2019, Jul-29, Volume: 63, Issue:4 Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Brazil; Cabergoline; Child; Drug Therapy, Combination; Female; Growth Hormone; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Predictive Value of Tests; Receptors, Somatostatin; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult	2019
The role of primary pharmacological therapy in acromegaly. Pituitary, 2014, Volume: 17 Suppl 1 Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Ergolines; Human Growth Hormone; Humans; Male; Octreotide; Pituitary Neoplasms; Somatostatin; Young Adult	2014
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. Clinical endocrinology, 2014, Volume: 81, Issue:6 Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Drug Therapy, Combination; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Injections, Subcutaneous; Insulin-Like Growth Factor I; Lipodystrophy; Male; Middle Aged; Octreotide; Receptors, Somatotropin; Retrospective Studies; Spain; Treatment Failure; Treatment Outcome	2014
[Contemporary options and perspectives in the treatment of acromegaly]. Casopis lekaru ceskych, 2014, Volume: 153, Issue:3 Topics: Acromegaly; Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Octreotide; Peptides, Cyclic; Radiosurgery; Receptors, Somatotropin; Somatostatin	2014
[Pituitary apoplexy in a young woman]. Ugeskrift for laeger, 2014, Apr-22, Volume: 176, Issue:17 Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Apoplexy; Pituitary Neoplasms	2014
Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. Clinical endocrinology, 2015, Volume: 82, Issue:5 Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Receptors, Dopamine D2; RNA, Messenger; Treatment Outcome	2015
Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors. European journal of endocrinology, 2015, Volume: 172, Issue:6 Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Drug Therapy, Combination; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Male; Middle Aged; Remission Induction; Somatostatin; Treatment Outcome; Young Adult	2015
Prolactinomas: evolution after menopause. Archives of endocrinology and metabolism, 2016, Volume: 60, Issue:1 Topics: Adenoma; Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Withholding Treatment	2016
Chronic cluster headache and the pituitary gland. The journal of headache and pain, 2016, Volume: 17 Topics: Adenoma; Cabergoline; Central Nervous System Cysts; Cluster Headache; Diagnosis, Differential; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Sumatriptan; Treatment Outcome; Verapamil	2016
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. European journal of endocrinology, 2016, Volume: 175, Issue:1 Topics: Adenoma; Adult; Aged; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Receptors, Dopamine; Receptors, Estrogen; Treatment Outcome	2016
Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes. Obstetrics and gynecology, 2017, Volume: 129, Issue:1 Topics: Adenoma; Adult; Amenorrhea; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cesarean Section; Dopamine Agonists; Ergolines; Female; Galactorrhea; Humans; Incidence; Pituitary Neoplasms; Pre-Eclampsia; Preconception Care; Pregnancy; Pregnancy Complications, Neoplastic; Premature Birth; Prolactinoma; Prospective Studies; Stillbirth; United Kingdom; Vision Disorders; Young Adult	2017
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocrine-related cancer, 2008, Volume: 15, Issue:2 Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Cell Division; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Female; Fibroblasts; Humans; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Receptors, Dopamine D2; Receptors, Somatostatin; RNA, Messenger; Somatostatin; Sulpiride; Thymidine; Tritium; Tumor Cells, Cultured	2008
Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly. Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:1 Topics: Acromegaly; Adenoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Cyclophosphamide; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Lymphoma, Non-Hodgkin; Male; Neoplasms, Multiple Primary; Octreotide; Prednisone; Thyroid Neoplasms; Thyroidectomy; Thyroxine; Vincristine	2009
Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. European journal of endocrinology, 2008, Volume: 159, Issue:5 Topics: Acromegaly; Adenoma; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Medical Audit; Middle Aged; Pituitary Gland; Prospective Studies; Treatment Outcome	2008
McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report. Arquivos brasileiros de endocrinologia e metabologia, 2009, Volume: 53, Issue:1 Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents, Hormonal; Cabergoline; Ergolines; Facial Bones; Female; Fibrous Dysplasia, Polyostotic; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Pituitary Neoplasms; Skull	2009
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:2 Topics: Adenoma; Aged; Apoptosis; Cabergoline; Cell Line, Tumor; Cell Survival; Ergolines; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Pituitary Neoplasms; Receptors, Somatostatin; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Somatostatin; Vascular Endothelial Growth Factor A	2010
A double pituitary adenoma presenting as a prolactin-secreting tumor with partial response to medical therapy. Case report. Endocrine pathology, 2010, Volume: 21, Issue:2 Topics: Adenoma; Adult; Antineoplastic Agents; Breast Neoplasms, Male; Cabergoline; Combined Modality Therapy; Ergolines; Gonadotrophs; Humans; Male; Microscopy, Electron, Transmission; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Neurofibromatosis 1; Neurosurgical Procedures; Prolactinoma	2010
Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression. Pituitary, 2011, Volume: 14, Issue:1 Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Cabergoline; Ergolines; Hemoglobins; Humans; Hypogonadism; Male; Middle Aged; Prolactin; Prolactinoma; Retrospective Studies; Testosterone	2011
Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary, 2011, Volume: 14, Issue:1 Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Child; Dopamine Agents; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult	2011
Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary, 2011, Volume: 14, Issue:2 Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Delayed-Action Preparations; Drug Resistance, Neoplasm; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide; Time Factors; Young Adult	2011
Two diagnostic pitfalls mimicking a prolactin-secreting microadenoma. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:12 Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Ergolines; Female; Galactorrhea; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Menstruation Disturbances; Pituitary Neoplasms; Prolactin	2010
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clinical endocrinology, 2012, Volume: 76, Issue:3 Topics: Adenoma; Adult; Cabergoline; Cell Proliferation; Dopamine; Dopamine Agonists; Drug Synergism; Ergolines; Gene Expression; Humans; Immunohistochemistry; Male; Octreotide; Pituitary Neoplasms; Protein Isoforms; Receptors, Dopamine D2; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; Somatostatin; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine; Tumor Cells, Cultured	2012
Extralabel use of cabergoline in the treatment of a pituitary adenoma in a rat. Journal of the American Veterinary Medical Association, 2011, Sep-01, Volume: 239, Issue:5 Topics: Adenoma; Animals; Antineoplastic Agents; Cabergoline; Ergolines; Male; Pets; Pituitary Neoplasms; Rats; Rodent Diseases	2011
Von Hippel-Lindau disease and aggressive GH-PRL pituitary adenoma in a young boy. Annales d'endocrinologie, 2012, Volume: 73, Issue:1 Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Human Growth Hormone; Humans; Magnetic Resonance Imaging; Male; Mutation; Pituitary Neoplasms; Prolactin; Somatostatin; Treatment Outcome; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein	2012
Disappearance of pituitary macro adenoma with combination of ketoconazole and cabergoline treatment: an unusual case of Cushing's syndrome with interesting findings. BMJ case reports, 2012, Jul-03, Volume: 2012 Topics: 14-alpha Demethylase Inhibitors; Adenoma; Adult; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Diagnosis, Differential; Drug Therapy, Combination; Ergolines; Humans; Ketoconazole; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Severity of Illness Index; Tomography, X-Ray Computed	2012
Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocrine journal, 2013, Volume: 60, Issue:4 Topics: Acromegaly; Adenoma; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Delayed-Action Preparations; Drug Resistance; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Octreotide; Pituitary Gland; Retrospective Studies; Somatostatin; Tumor Burden; Young Adult	2013
Hyperprolactinemia: an unusual cause of erectile dysfunction. Archives of sexual behavior, 2013, Volume: 42, Issue:3 Topics: Adenoma; Adult; Cabergoline; Dopamine Agonists; Erectile Dysfunction; Ergolines; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Treatment Outcome	2013
Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:11 Topics: Adenoma; Antineoplastic Agents; Body Height; Cabergoline; DNA Mutational Analysis; Ergolines; Fibrous Dysplasia, Polyostotic; GTP-Binding Protein alpha Subunits, Gs; Human Growth Hormone; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Octreotide; Pituitary Neoplasms	2002
Dopamine receptor expression and function in corticotroph pituitary tumors. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:5 Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Pituitary Neoplasms; Radioligand Assay; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured	2004
Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy. Age and ageing, 2004, Volume: 33, Issue:4 Topics: Adenoma; Aged; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hydrocephalus; Male; Pituitary Neoplasms; Prolactinoma	2004
Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Hormone research, 2004, Volume: 62, Issue:6 Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Cyproheptadine; Dopamine Agonists; Ergolines; Female; Hormone Replacement Therapy; Humans; Magnetic Resonance Imaging; Nelson Syndrome; Pituitary Neoplasms	2004
Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. Journal of endocrinological investigation, 2004, Volume: 27, Issue:11 Topics: Adenoma; Adrenocorticotropic Hormone; Cabergoline; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Receptors, Dopamine D2; Treatment Outcome	2004
Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma. Pituitary, 2004, Volume: 7, Issue:2 Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Ergolines; Humans; Hypopituitarism; Magnetic Resonance Imaging; Male; Pituitary Diseases; Pituitary Neoplasms; Prolactin; Prolactinoma; Stroke	2004
Cabergoline decreases somatotroph adenoma size: a case report. Pituitary, 2004, Volume: 7, Issue:2 Topics: Adenoma; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cabergoline; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Pituitary Neoplasms; Treatment Outcome	2004
The clinical characteristics of headache in patients with pituitary tumours. Brain : a journal of neurology, 2005, Volume: 128, Issue:Pt 8 Topics: Adenoma; Adult; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Disability Evaluation; Dopamine Agonists; Ergolines; Female; Headache; Humans; Male; Migraine Disorders; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Severity of Illness Index; Somatostatin; Time Factors	2005
Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. Fertility and sterility, 2006, Volume: 86, Issue:3 Topics: Adenoma; Adult; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms	2006
Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? European journal of endocrinology, 2006, Volume: 155, Issue:5 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aminoquinolines; Benzamides; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon	2006
Reduced growth of beard as the only diagnostic sign in a patient with macroprolactinoma. Journal of the European Academy of Dermatology and Venereology : JEADV, 2007, Volume: 21, Issue:1 Topics: Adenoma; Adult; Cabergoline; Dopamine Agonists; Ergolines; Face; Hair; Humans; Hydrocortisone; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Testosterone; Thyroxine	2007
[Predictive value of the Knosp classification in grading the surgical resection of invasive pituitary macroadenomas. A prospective study of 23 cases]. Neurocirugia (Asturias, Spain), 2006, Volume: 17, Issue:6 Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Cabergoline; Cavernous Sinus; Combined Modality Therapy; Cranial Irradiation; Diabetes Insipidus, Neurogenic; Dose Fractionation, Radiation; Endoscopy; Ergolines; Female; Follow-Up Studies; Humans; Hypophysectomy; Magnetic Resonance Imaging; Male; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pituitary Neoplasms; Postoperative Complications; Predictive Value of Tests; Prognosis; Prospective Studies; Radiography; Radiotherapy, Adjuvant; Somatostatin; Sphenoid Bone; Treatment Outcome	2006
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. Journal of endocrinological investigation, 2006, Volume: 29, Issue:11 Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Ergolines; Humans; Somatostatin	2006
Dopaminergic treatment of nonfunctioning pituitary adenomas. Nature clinical practice. Endocrinology & metabolism, 2007, Volume: 3, Issue:8 Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine Agents; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactin	2007
Management of type 2 diabetes mellitus associated with pituitary gigantism. Pituitary, 2007, Volume: 10, Issue:4 Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diabetes Mellitus, Type 2; Ergolines; Gigantism; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pituitary Neoplasms; Radiotherapy	2007
An important new adaption of a specific drug? Fertility and sterility, 2007, Volume: 88, Issue:2 Topics: Adenoma; Antineoplastic Agents; Cabergoline; Ergolines; Female; Gonadotropins; Humans; Neovascularization, Pathologic; Ovarian Hyperstimulation Syndrome; Pituitary Neoplasms; Polycystic Ovary Syndrome; Vascular Endothelial Growth Factor A	2007
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. The pharmacogenomics journal, 2008, Volume: 8, Issue:5 Topics: Adenoma; Adult; Alleles; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Pituitary Neoplasms; Polymorphism, Genetic; Prolactin; Receptors, Dopamine D2; Retrospective Studies	2008
Effectiveness of cabergoline in reducing follicle-stimulating hormone and prolactin hypersecretion from pituitary macroadenoma in an infertile woman. Fertility and sterility, 1994, Volume: 62, Issue:4 Topics: Adenoma; Adult; Amenorrhea; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Humans; Infertility, Female; Pituitary Neoplasms; Pregnancy; Prolactin	1994
Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:6 Topics: Adenoma; Adolescent; Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Gonads; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Visual Fields	1996
Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone. Postgraduate medical journal, 1997, Volume: 73, Issue:862 Topics: Adenoma; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Follicle Stimulating Hormone; Humans; Male; Middle Aged; Pituitary Neoplasms	1997
Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. Journal of endocrinological investigation, 1997, Volume: 20, Issue:9 Topics: Adenoma; Adolescent; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Kinetics; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactin	1997
Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. Journal of endocrinological investigation, 1999, Volume: 22, Issue:4 Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactin; Time Factors	1999
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. The Journal of clinical endocrinology and metabolism, 1999, Volume: 84, Issue:7 Topics: Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Tolerance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Retrospective Studies; Sex Characteristics	1999
Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. Journal of endocrinological investigation, 1999, Volume: 22, Issue:11 Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Antineoplastic Agents; Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Nelson Syndrome; Pituitary Neoplasms; Remission Induction	1999
In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clinical endocrinology, 2001, Volume: 54, Issue:1 Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Prognosis; Thyrotropin	2001
ACTH silent adenoma shrinking under cabergoline. European journal of endocrinology, 2001, Volume: 144, Issue:1 Topics: Adenoma; Adrenocorticotropic Hormone; Aged; Antineoplastic Agents; Autoradiography; Cabergoline; Ergolines; Humans; In Situ Hybridization; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2; RNA, Messenger	2001
Long-term treatment of thyrotropin-secreting microadenoma with lanreotide and cabergoline. European journal of endocrinology, 2001, Volume: 144, Issue:2 Topics: Adenoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cabergoline; Ergolines; Female; Humans; Peptides, Cyclic; Somatostatin; Thyrotropin; Time Factors	2001
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. Journal of endocrinological investigation, 2001, Volume: 24, Issue:2 Topics: Acromegaly; Adenoma; Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Ergolines; Female; Headache; Human Growth Hormone; Humans; Male; Neoplasm Recurrence, Local; Octreotide; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed; Radiotherapy; Treatment Outcome; Vision Disorders; Visual Fields	2001
Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report. Pituitary, 2000, Volume: 3, Issue:4 Topics: Abdominal Pain; Acromegaly; Adenoma; Adult; Anti-Bacterial Agents; Bile Ducts, Intrahepatic; Bilirubin; Cabergoline; Chemical and Drug Induced Liver Injury; Cholangiopancreatography, Endoscopic Retrograde; Cholelithiasis; Cholesterol; Ergolines; Gram-Negative Bacterial Infections; Hepatectomy; Humans; Insulin-Like Growth Factor I; Liver; Liver Diseases; Male; Octreotide; Pituitary Neoplasms; Postoperative Complications; Sepsis; Surgical Wound Infection	2000
New perspectives in medical management of hyperprolactinemia. Endocrinologia experimentalis, 1990, Volume: 24, Issue:1-2 Topics: Adenoma; Bromocriptine; Cabergoline; Delayed-Action Preparations; Empty Sella Syndrome; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms	1990
Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. The Journal of clinical endocrinology and metabolism, 1989, Volume: 69, Issue:4 Topics: Adenoma; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin	1989
Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary. European journal of pharmacology, 1988, Jun-22, Volume: 151, Issue:1 Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Bromocriptine; Cabergoline; DNA, Neoplasm; Ergolines; Estrogens; Female; Mitosis; Pituitary Neoplasms; Prolactin; Rats	1988